<DOC>
	<DOCNO>NCT02733133</DOCNO>
	<brief_summary>This study assess potential Testagen® TDS-Testosterone enable transfer Testosterone females come contact skin Testagen® TDS-Testosterone apply potential product raise serum androgen level woman .</brief_summary>
	<brief_title>Product Transference Study Testagen™ TDS®-Testosterone</brief_title>
	<detailed_description>48 Couples add protocol single dose apply male member couple . The female member couple undergone baseline pharmacokinetic monitoring endogenous level Testosterone . At precise interval cohort day trial , male expose skin onto trial material apply skin partner undergo another 24-hour multiple sample monitoring level testosterone .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Healthy Volunteers 2 . Subject Couples , 18 80 year age , inclusive . 3 . The subject couple willing able read , understand Subject Information Sheets provide write informed consent . 4 . The subject body mass index ( BMI ) within 1830 kg/m2 . 5 . The subject otherwise good health determine medical history physical examination . 6 . Female subject must practice acceptable method birth control . Acceptable method birth control include hormonal contraceptive . If practice acceptable method birth control , negative urine pregnancy test result obtain Treatment Day . 7 . The subject nonsmoker . 8 . The female subject must agree comply placement indwell catheter two separate occasion draw blood sample pharmacokinetic assessment . 9 . The subject couple willing able comply test requirement define protocol . 10 . The subject couple willing able return study site visit . 1 . The subject relevant deviation normal physical examination , electrocardiogram ( ECG ) , clinical laboratory test , evaluate investigator , particularly elevate PSA read positive pregnancy test . 2 . The subject clinically significant illness within 30 day precede entry study . 3 . The subject history significant neurological , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , metabolic disease . 4 . The subject know allergy history hypersensitivity Testosterone similar compound . 5 . The subject use prescription medication within 14 day overthecounter ( OTC ) medication alcohol within 48 hour dose intend use prescription OTC medication study may interfere evaluation study medication ( exclude oral contraceptive ) . 6 . The subject donate lost significant volume blood ( &gt; 450mL ) within four ( 4 ) week study , haemoglobin concentration haematocrit return within 5 % normal . 7 . The subject history substance abuse current positive urine drug screen . 8 . Alcohol consumption great community norm ( i.e . 21 standard drink per week male , 14 female ) . 9 . Subjects receive investigational drug use investigational device 30 day prior study entry . 10 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>AndroGel</keyword>
	<keyword>Transference</keyword>
	<keyword>Women</keyword>
	<keyword>Children</keyword>
</DOC>